

Amendments to the Claims:

Please cancel claims 1-67, and add the following new claims 68-78.

1-67 (canceled)

68. (New) A method of modifying drug pharmacokinetics in a patient in need thereof comprising administering to said patient Ecteinasclidin-743 in an amount effective to modify drug pharmacokinetics in said patient but which has minimal cytotoxic effects.

69. (New) A method of modifying drug metabolism in a cell comprising administering to said cell Ecteinasclidin-743 in an amount effective to modify drug metabolism in said cell, but which has minimal cytotoxic effects on said cell.

70. (New) The method of claim 68, wherein Ecteinasclidin-743 is administered in concentrations of up to about 50nM.

71. (New) The method of claim 69, wherein Ecteinasclidin-743 is administered in concentrations of up to about 50nM.

72. (New) The method of claim 68, wherein Ecteinasclidin-743 is administered in concentrations of about 3nM to about 50nM.

73. (New) The method of claim 69, wherein Ecteinasclidin-743 is administered in concentrations of about 3nM to about 50nM.

74. (New) The method of claim 68, wherein Ecteinasclidin-743 is administered in concentrations of about 25nM to about 50nM.

75. (New) The method of claim 69, wherein Ecteinasclidin-743 is administered in concentrations of about 25nM to about 50nM.

76. (New) The method of claim 68, wherein Ecteinasclidin-743 antagonizes SXR.

77. (New) The method of claim 69, wherein Ecteinasclidin-743 antagonizes SXR.

78. (New) In a method of treating a patient with a drug, the improvement comprising co-administering Ecteinasclidin-743 to said patient in an amount effective to modify drug pharmacokinetics but which has minimal cytotoxic effects.